Stifel Nicolaus Boosts Clovis Oncology Inc. (CLVS) Price Target to $45.00
Posted by Amy Steele on Sep 21st, 2016 // No Comments
Clovis Oncology Inc. (NASDAQ:CLVS) had its target price increased by investment analysts at Stifel Nicolaus from $30.00 to $45.00 in a research report issued to clients and investors on Wednesday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock.
Stifel Nicolaus’ price objective would suggest a potential upside of 29.20% from the stock’s current price.
Several hedge funds have recently bought and sold shares of the stock. Parametric Portfolio Associates LLC acquired a new stake in Clovis Oncology during the second quarter worth about $144,000. Fox Run Management L.L.C. purchased a new position in shares of Clovis Oncology during the second quarter worth $154,000. Legal & General Group Plc increased its position in shares of Clovis Oncology by 56.8% in the first quarter. Legal & General Group Plc now owns 8,483 shares of the biopharmaceutical company’s stock worth $164,000 after buying an additional 3,072 shares during the last quarter. CIBC World Markets Inc. increased its position in shares of Clovis Oncology by 7.8% in the first quarter. CIBC World Markets Inc. now owns 11,680 shares of the biopharmaceutical company’s stock worth $224,000 after buying an additional 850 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC purchased a new position in shares of Clovis Oncology during the first quarter worth $233,000. Institutional investors own 98.46% of the company’s stock.
AI
